期刊文献+

重组HER2真核表达载体的构建及其稳定转染EMT6细胞株的筛选 被引量:4

Construction of an eukaryotic plasmid encoding HER2 and screening of a cell line stably expressing clones
下载PDF
导出
摘要 目的:构建人表皮生长因子受体(HER2)胞外区(1896bp)基因的真核表达质粒(pcDNA6/v5-his-HER2),转染小鼠乳腺癌细胞(EMT6),获得其稳定表达细胞株(EMT6/HER2)。方法:用PCR方法从含HER2全长基因的pcDNA3.1-HER2质粒上扩增HER2胞外区基因序列;经酶切、连接构建pcDNA6/v5-his-HER2;转化大肠杆菌DH5α,筛选阳性克隆,对其进行酶切及测序鉴定;以PEI法将pcDNA6/v5-his-HER2导入EMT6小鼠乳腺癌细胞,经杀稻瘟菌素(Blasticidin)筛选1~2周,获得抗性克隆EMT6/HER2;用RT-PCR检测EMT6/HER2中HER2mRNA,免疫组化法检测其HER2蛋白的表达。结果:PCR产物与预期片段大小一致;pcDNA6/v5-his-HER2经酶切、琼脂糖凝胶电泳后,可见与PCR产物大小相同的片段;DNA测序结果显示,pcDNA6/v5-his-HER2中HER2基因序列无误,读码框正确;用RT-PCR可在EMT6/HER2中检测到HER2mRNA,免疫组化法证实,EMT6/HER2中有HER2的阳性信号。结论:成功地构建了HER2胞外区真核表达载体,获得稳定表达HER2基因的小鼠乳腺癌EMT6细胞株,为进一步研究HER2基因过表达与乳腺癌发生的关系及其基因治疗奠定基础。 AIM:To construct an eukaryotic vector encoding extracellular domain of human epidermal growth factor receptors(HER2),pcDNA6/v5-his-HER2,and to screen HER2 positive clones from mouse breast cancer cell line EMT6.METHODS:The extracellular domain of HER2 was amplified from pcDNA3.1-HER2 by PCR.pcDNA6/v5-his-HER2 was prepared by inserting the fragment into the plasmid pcDNA6/v5-his.Then the recombinant vector was identified by restriction enzyme and sequencing.Next,pcDNA6/v5-his-HER2 was transfected into the EMT6 cell line and the positive clones(EMT6/HER2)were screened with blasticidin.Finally,the expression of HER2 in EMT6/HER2 was detected by RT-PCR and immunohistochemistry.RESULTS:The fragment of HER2 was amplified and pcDNA6/v5-his-HER2 was prepared successfully.No errors were found both in the sequence and ORF of the acquired fragment.The expected fragment of HER2(1896 bp)was amplified from EMT6/HER2 by RT-PCR and positive signals of HER2 were detected in EMT6/HER2 by immunohistochemistry.CONCLUSION:An eukaryotic plasmid encoding HER2(pcDNA6/v5-his-HER2)has been constructed and a cell line expressing HER2 stably has been prepared successfully.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2009年第3期226-228,232,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 青岛市科技局基金资助项目(05-12-NS-29)
关键词 HER2 真核表达 转染 HER2 eukaryotic expression transfection
  • 相关文献

参考文献3

二级参考文献18

  • 1王妮.避孕疫苗[A].李忠明主编.当代新疫苗[C].北京:高等教育出版社,2001.126-139.
  • 2Coussens L, Yang Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene [ J]. Science, 1985,230(4 730) : 1132- 1139.
  • 3Brennan PJ, Kumagai T, Berezov A, et al. HER2/neu:mechanisms of dimerization / oligomerization[ J ]. Oncogene,.2000, 19(53) :6093 - 6101.
  • 4Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situhybridization [J]. Proc Natl Acad Sci USA, 1992, 89(12):5321 - 5325.
  • 5Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of c-erbB2 expression in breast cancer[J] .J Surg Oncol, 2002,79(4) :216 - 223.
  • 6Lu J, Cells E. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes[J]. Cancer Res, 2000, 60(18):5223 - 5227.
  • 7Ward RL, Hawkins N J, Coomber D, et al. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer[J]. Hum Immunol, 1999, 60(6) :510 - 515.
  • 8Disis ML, Smith JW, Murphy AE, et al. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein [ J]. Cancer Res,1994, 54(4):1071 - 1076.
  • 9Kono K, Rongcun Y, Charo J, et al. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes[J]. Int J Cancer, 1998, 78(2) :202 - 208.
  • 10Disis ML, Cooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines[J]. J Clin Oneol,2002, 20(11): 2624 -2632.

共引文献10

同被引文献31

  • 1孙文欣,林晨,张叔人.HER-2/neu基因在肿瘤免疫治疗中的研究进展[J].国外医学(免疫学分册),2005,28(1):13-16. 被引量:3
  • 2张文卿,王丽娜,刘志军,Dernard Mariameb,于红,杨忠思,于修平.用细胞因子流式细胞计数术体外检测重组人IL-12的生物学活性[J].中华微生物学和免疫学杂志,2006,26(4):383-384. 被引量:9
  • 3孙运芳,张文卿,王丽娜,于红,李丹.人IL-12重组质粒对S-180荷瘤小鼠的治疗作用[J].中华肿瘤防治杂志,2007,14(5):349-351. 被引量:9
  • 4Dimitriadis A, Gontinou C, Baxevanis CN, et al. The mannosylated extracellular domain of her2/neu produced in P.pastoris induces protective antitumor immunity [J]. BMC Cancer, 2009, 9: 386.
  • 5Wei MQ, Ellem OA, Dunn P, et al. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours [J]. Eur J Cancer, 2007, 43 (3): 490-496.
  • 6Vaupel P, Kelleher DK, H~ckel M. Oxygen status of malignant tumors:pathogenesis of hypoxia and significance for tumor therapy[J~ Semin Oncol, 2001, 28(2 Suppl 8): 29-35.
  • 7Lambin P, Theys J, Landuyt W, et al. Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours[J]. Anaerobe, 1998, 4(4): 183-188.
  • 8Mermelstein LD, Welker NE, Bennett GN, et al. Expression of cloned homologous fermentative genes in c|ostridium acetobutylicum ATCC 824[J]. Biotechnology(NY), 1992, 10(2): 190-195.
  • 9Liu SC, Minton NP, Giaccia A J, et al. Anficancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis [J]. Gene Ther, 2002, 9(4): 291-296.
  • 10Theys J, Pennington O, Dubois L, et al. Repeated cycles of clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo [J]. Br J Cancer, 2006, 95(9): 1212-1219.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部